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Background: A circadian rhythm of symptoms has been reported in allergic rhinitis (AR). 
Severity of all major symptoms of AR, including runny nose, sneezing, and nasal congestion, 
is typically at its peak in the morning. The objective of this study was to explore the efficacy 
of the antihistamine and platelet activating factor (PAF) antagonist rupatadine in the morning 
and evening and to evaluate whether rupatadine provides effective symptom relief throughout 
the 24-hour dosing interval.
Methods: A total of 308 patients 18 years of age with PAR was randomly assigned to once-
daily rupatadine 10 mg, rupatadine 20 mg, or cetirizine 10 mg for 4 weeks in a placebo-controlled, 
double-blind study. The main outcome was the morning/evening reflective total symptom score 
(5TSS) over the treatment period. Secondary endpoints included morning/evening reflective 
nasal total symptom score (4NTSS), individual symptoms, Pdmax1 as percentage of days with 
daily severest symptom score #1, and subject/investigator evaluation of therapeutic response.
Results: All active groups were significantly more effective than placebo in improving morning 
and evening evaluations of 5TSS (P , 0.001) and 4NTSS (P , 0.001) at 2 or 4 weeks. At   morning 
evaluation, there was a significant reduction from baseline for 5TSS with rupatadine 10 mg 
(−36.8%, P , 0.01) and 20 mg (−46.3%, P , 0.01) compared with placebo. Similarly, 4NTSS 
was reduced significantly more with rupatadine 10 mg (−34%, P , 0.05) and 20 mg (−41%, 
P , 0.01) compared with placebo. In the cetirizine 10 mg group, the reduction was −32.7% 
and −32.2% for 5TSS and 4NTSS, respectively, but this reduction was not significant compared 
with placebo. The percentage reduction was greater at evening than at morning   evaluation. 
5TSS reduction with rupatadine 10 mg (−40.7%, P , 0.05) and 20 mg (−49.9%, P , 0.01) 
and cetirizine 10 mg (−40.1%, P , 0.05) was significantly better than with placebo. 4NTSS 
values for active groups were also significantly improved versus placebo. When individual 
symptoms were assessed, statistically significant differences for rhinorrhea (P , 0.01), nasal 
itching (P , 0.01), and sneezing (P , 0.01) were shown in all active groups compared with 
placebo at morning and evening evaluations. Pdmax1 index was significantly improved for all 
active groups and the overall efficacy assessed by patients or investigators showed a significant 
improvement (P , 0.01) versus placebo at 2 and 4 weeks. The incidence of somnolence was 
significantly greater in all active groups versus placebo.
Conclusion: The sustained 24-hour action of rupatadine 10 mg provides an effective control 
of morning and evening symptoms in patients with PAR treated for up to 4 weeks.
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Introduction
Many inflammatory diseases exhibit variations in symptoms 
over time, and symptoms of allergic rhinitis (AR) have been 
shown to follow a pattern of circadian variation.1 Severity 
of symptoms of AR is typically greatest in the morning 
for all major symptoms, including runny nose, sneezing, 
and nasal congestion.2 Possible etiologies of increased 
morning symptoms include increased levels of histamine 
and other inflammatory mediators.3 Patients report that 
morning symptoms reduce quality of life throughout the 
rest of the day. Therefore, an important consideration in 
the pharmacologic treatment of AR is the effective relief of 
morning symptoms.
Second-generation oral antihistamines are among the 
most widely prescribed agents due to their effectiveness in the 
treatment of allergic diseases. Although newer long-acting 
antihistamine preparations permit once-daily dosing, many 
patients with AR experience breakthrough symptoms and a 
reduction of clinical potency at the end of the dosing interval. 
Most antihistamines demonstrate a peak effect approximately 
5 to 7 hours after oral administration, and the duration varies 
depending on the half-life of parent compound and active 
metabolites.4
The aim of this study was to examine the efficacy of 
rupatadine, a new antihistamine H1 and PAF antagonist,5–7 
which provides effective symptom relief throughout the 
24-hour dosing interval in patients with perennial AR (PAR).
Methods
study design and treatments assessed
This was a randomized, double-blind, parallel-group, 
placebo-controlled, comparative study of rupatadine 10 mg 
(R10), rupatadine 20 mg (R20), and cetirizine 10 mg (C10). 
All 4 treatments (3 active and placebo) were administered 
orally in identical tablets each morning within 1 hour after 
awakening. A total of 61 French medical allergologists and 
pneumologists participated in the trial. The trial complied 
with local Ethical Committees and Good Clinical Practice 
guidelines and local clinical trial regulations. All patients 
gave their written informed consent before being included 
in the study.
inclusion and exclusion criteria
Patients aged 18 years old with a diagnosis of PAR for at 
least 12 months, and with a total nasal symptom score 5, 
were included into the study. During a screening visit, the 
patients had to show a positive skin prick test (diameter of 
the papule .3 mm compared with saline solution control, 
or  than histamine at a 10 mg/mL dilution) at inclusion 
or within 1 year before inclusion. The allergens used in the 
prick test are usually related to PAR: house dust mites, cat 
and dog hair, molds, and feathers. Atopic patients with PAR 
symptoms and seasonal deterioration during the pollen season 
were allowed to participate in the study. A normal 12-lead 
ECG had to be documented at the pre-screening visit with 
the following requirements: QTc , 430 msec for males, 
and QTc , 450 msec for females. Women of childbearing 
age had to show a negative pregnancy test and had to use 
contraceptive measures during the study.
Patients suffering from nonallergic rhinitis (eg, vasomotor, 
infectious, or drug-induced rhinitis) or with a negative prick 
test were not included. Treatments with nasal descongestants 
in the previous 24 hours, oral antihistamines or disodium 
chromoglycate (previous week), ketotifen (previous month), 
topical antihistamines (previous 48 hours), systemic or 
topical treatment with corticosteroids (except for topical 
hydrocortisone , 1%), immunosuppressants, or any 
investigational drug within 2 weeks prior to inclusion, 
were also considered as exclusion criteria. Other relevant 
exclusion criteria included abnormal laboratory values of 
clinical significance; certain conditions that may interfere with 
response to treatment such as mild asthma treated with inhaled 
bronchodilators or inhaled corticosteroids .800 µg/day of 
budesonide or beclomethasone, or with .500 µg/day of 
fluticasone; obstructive nasal polyps; or hypersensitivity to 
compounds structurally related to the study drug.
Evaluation of efficacy
Each patient received a diary card for daily recording of 
symptoms at the start of the treatment. Severity scores for 
5 (5TSS) individual AR signs/symptoms: nasal (rhinorrhea, 
sneezing, nasal itching, and nasal obstruction), and non-nasal 
symptoms (conjunctival itching) were recorded on the diary 
card every morning (morning) within 1 hour of awakening 
and prior to dosing (reflective) and every night (evening) at 
bed-time approximately 12 hours later. In both the morning 
and evening symptom severity was assessed over the previous 
12 hours (reflective) and scored numerically on a scale of 0–3 
with 0 = absent, 1 = mild, 2 = moderate, or 3 = severe. The 
5TSS is the sum of the ratings for the individual scores.
The investigators examined the patient’s diary card 
at each follow-up visit (days 14 ± 3 and 28 ± 3) to check 
treatment compliance and to provide any advice.
Furthermore, a Pdmax1 index was calculated as the 
percentage of days during the study for each patient when the 
score of the daily most severe symptom score was #1.Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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Patient and investigator evaluation of therapeutic 
response to treatment at 2 and 4 weeks was also assessed. 
In these 2 follow-up visits, the patient’s and physician’s 
global evaluation of efficacy was scored numerically on a 
scale of 0 = worsened, 1 = no change, 2 = slight improvement, 
and 3 = good improvement.
evaluation of safety
Treatment safety and tolerability were evaluated according 
to the incidence and type of adverse events spontaneously 
reported in the patient’s diary or reported as an answer to the 
investigator’s question of: “Have you noticed any discomfort 
during these days” at each visit.
Laboratory safety tests (complete blood count and 
standard serum chemistry), physical examinations, all 
  performed during the study as well as at the end of the study 
period, were considered. All adverse events were coded using 
the WHO Adverse Reactions terminology dictionary, and 
grouped by treatment.
statistical analysis
It was calculated that 70 patients had to be included in each 
treatment group (for a total of 280 patients) in order to show 
the expected difference between active treatments and placebo 
of 20% in the main efficacy variable, taking into account a 
dropout rate of 10% and with a protection level of 0.05 against 
type I random errors and of 0.2 against type II errors.
Analysis of variance was used to compare treatment 
groups for the quantitative primary and secondary outcomes. 
In case of significant results, subsequent pairwise contrasts 
using a Bonferroni adjustment were made between the 
treatment groups. For quantitative (efficacy and safety) 
variables, mean, median, standard deviation, and maximum 
and minimum values were calculated.
Qualitative variables were expressed as relative 
  frequencies. Chi-square test was used for qualitative variables 
and Fisher’s test was used if the applicability conditions 
were not present. The Mantel–Haenszel chi-square test was 
performed if both variables lay on an ordinal scale.
Analysis of both efficacy and safety was based on 
intention to treat (ITT), including all patients who were 
randomized and received at least 1 dose of study medication. 
The adverse events were coded using the Medical Dictionary 
for Regulatory Activities (MedDRA® v 12.1) and the 
incidence of adverse events was compared between treatment 
groups using the chi-square test.
All statistical analyses were 2-tailed, with a significance 
level set at P , 0.05. Statistical analyses were performed using 
the SAS® statistical software (SAS Institute Inc, Cary, NC).
Results
study population
Patients were recruited from a total of 61 allergologists and 
pneumologists from several private centers in France. The dis-
position of patients during the study is shown in Figure 1.
A total of 308 patients were enrolled into the trial, but 26 
were not randomized and did not take any study treatment. 
Therefore, 282 patients were randomized. Of these, 273 took 
Dropout before any drug intake (6)
Lost to follow-up (3)
Poor diary card filled (4)
Patients screened
N = 308 
Patients randomized
N = 282 
Placebo
N = 70
Cetirizine 10 mg
N = 66
Rupatadine 10 mg
N = 65
Rupatadine 20 mg
N = 68
Screen failures (26)
Reasons:
Selection criteria (20)
Lost to follow-up (3)
Patient decision (3)  
ITT population
N = 269 
Figure 1 Disposition of patients during the study (iTT population).Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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at least 1 treatment dose and were evaluated for safety. Four 
patients showed incomplete and no valid information in their 
diaries and were excluded from the data analysis; therefore, 
the ITT population was 269 patients.
At baseline, demographic data showed there were no 
differences between relevant demographic and clinical 
characteristics (Table 1).
Efficacy of treatments
Tables 2 and 3 show the ITT analysis for morning and 
evening score indexes at baseline, and at 2 and 4 weeks of 
treatment, considering the absolute values and the percentage 
reduction from baseline.
All active groups showed a significant reduction in 
symptoms score at morning and evening evaluations, and 
both 5TSS (P , 0.001) and 4NTSS (P , 0.001) at 2 or 
4 weeks showed significant improvements in the ANOVA 
comparison with placebo.
At the morning evaluations at 4 weeks, there were 
  significant reductions of −36.8% from baseline in the primary 
endpoint (5TSS, reflective) in the R10 group (P , 0.01) 
and −46.3% in the R20 group (P , 0.01) compared with 
placebo. The C10 group reduction of −32.7% from baseline 
was not significant compared with placebo. At the morning 
evaluations at 4 weeks, there were also significant reductions 
in the 4NTSS for both R10 and R20 groups compared with 
placebo (−34%, P , 0.05 and −41%, P , 0.01, respectively). 
The C10 group reduction of −32.2% was not significant 
compared with placebo.
At the evening evaluations at 4 weeks, there was a 
significant reduction of 5TSS for both R10 and R20 groups 
(−40.7%, P , 0.05 and −49.9%, P , 0.01, respectively) 
compared with placebo. The C10 group also showed a 
significant reduction from baseline (−40.1%, P , 0.05) 
compared with placebo. The above pattern was similar 
for 4NTSS scoring: both R10 and R20 groups showed a 
significant reduction compared with placebo (−40.7%, 
P , 0.05 and −44.9%, P , 0.01, respectively) and C10 also 
showed a significant reduction (−39.9%, P , 0.05) compared 
with placebo.
When individual symptoms were assessed, statistically 
significant improvements in rhinorrhea (P , 0.01), nasal 
itching (P , 0.01), and sneezing (P , 0.01) were shown 
in all active groups compared with placebo at morning and 
evening evaluations. Nasal obstruction was significantly 
improved only in the R20 group compared with placebo at 
morning evaluations. A lesser reduction was detected for 
ocular symptoms at morning and evening evaluations in all 
active groups compared with placebo (Figure 2).
The reduction of 5TSS was also evaluated throughout the 
study and the circadian rhythm for each treatment group at 
morning and evening evaluation is shown in Figure 3.
All the active treatments were also significantly   better 
than placebo as evidenced by Pdmax1 mean   values: 
  placebo = 24.4%; C10 = 43% (P , 0.01); R10 40% 
(P , 0.01) and R20 49.6% (P , 0.001).
There was a significant difference between treatment 
groups (P = 0.001) for overall efficacy assessed by patients 
or investigators at 2 and 4 weeks. All 3 active treatments 
were evaluated as better than placebo and the differences in 
pairwise comparisons were statistically significant (P , 0.01) 
versus placebo at both periods. No difference was found in 
the comparisons between active treatments.
safety
Table 4 presents the incidence of adverse events occurring 
in 1% of patients in any group. There was no signifi-
cant difference between groups in the number of patients 
reporting adverse events, or in the total number of reported 
adverse events. No life-threatening adverse event occurred. 
The only adverse event showing a statistically significant 
difference was somnolence: R10 (11%) and R20 (20%) 
compared with placebo (P , 0.01 and P , 0.001, respec-
tively). Laboratory tests analysis and ECG parameters   
Table 1 Demographic and clinical characteristics at baseline in iTT population
Variable Placebo 
(n = 70)
Rupatadine 10 mg  
(n = 65)
Rupatadine 20 mg  
(n = 68)
Cetirizine 10 mg   
(n = 66)
gender (male %) 27 (38) 18 (27) 26 (37) 28 (41)
Age (years) 30.9 31.4 33.8 32.2
race (caucasian %) 69 (97) 65 (100) 68 (100) 63 (92)
5Tss mean value 6.96 6.62 6.28 6.23
4nTss mean value 6.15 5.65 5.50 5.45
Notes: 5Tss: total symptoms score was calculated by adding the 5 symptom scores: rhinorrhea, sneezing, nasal itching, nasal obstruction, and conjunctival itching; 4nTss: 
total nasal symptoms score was calculated by adding the 4 symptom scores: rhinorrhea, sneezing, nasal itching, and nasal obstruction. No significant differences were found 
between treatment groups.Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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(QTc interval) did not show any clinical relevant findings 
between groups.
Discussion
In the present study, conducted in adults, we have 
demonstrated that once-daily administration of rupatadine 
is significantly more effective than placebo in relieving 
the symptoms of PAR during the 4 weeks of treatment. 
Moreover, a clear and significant reduction in nasal 
and non-nasal symptoms score at morning and evening 
evaluations was seen in rupatadine groups compared with   
placebo.
The nonsedating H1 antihistamines are important 
medications in the treatment of all stages of AR severity 
and are recommended by current guidelines.8 Although 
newer second-generation antihistamines permit once-daily 
dosing, many patients experience breakthrough symptoms 
and a diminution of clinical potency at the end of the dosing 
interval.4 Over the 4-week follow-up period, the study aim 
was to evaluate if rupatadine provided a full 24-hour efficacy 
in our PAR patients.
The symptoms of AR vary in severity over the course 
of the day and are often worse in the morning. In AR the 
intensity of nasal congestion, rhinorrhea, and sneezing 
are greatest early in the morning in approximately 70% of 
patients.9,10 This was true both for patients with seasonal 
symptoms alone (55.9%) and for those with PAR (65.7%), 
although it is noteworthy that those with PAR reported 
Table 2 Summary of morning (morning reflective) total symptoms score (5TSS) and nasal total symptoms score (4NTSS) assessments 
(iTT population)
Placebo Rupatadine 
10 mg
Rupatadine 
20 mg
Cetirizine 
10 mg
ANOVA
Mean SEM Mean SEM Mean SEM Mean SEM P value
Baseline 5Tss 6.96 0.36 6.62 0.36 6.28 0.37 6.23 0.36 ns
4nTss  6.15 0.30 5.65 0.32 5.50 0.33 5.45 0.31 ns
2 weeks 5Tss 5.82 0.34 4.36** 0.25 3.90** 0.27 4.32** 0.29 ,0.001
4nTss 5.18 0.30 3.81** 0.22 3.47** 0.23 3.75** 0.24 ,0.001
4 weeks 5Tss 5.52 0.36 4.04** 0.26 3.45** 0.25 3.88** 0.3 ,0.001
4nTss 4.97 0.32 3.50** 0.23 3.06** 0.22 3.33** 0.24 ,0.001
change from baseline  
(4 weeks)
5Tss −1.45 0.33 −2.64* 0.33 −2.81** 0.34 −2.36 0.36 0.023
4nTss −1.21 0.26 −2.17* 0.29 −2.43** 0.31 −2.08* 0.31 0.021
% change from baseline 5Tss −21.2 4.2 −36.8** 4.2 −46.3** 3.72 −32.7 4.6 0.001
4nTss −21.2 3.9 −34.0* 4.2 −41.0** 5.34 −32.2 4.7 0.022
Notes: *P , 0.05 vs placebo; **P , 0.01 vs placebo.
Abbreviation: NS, not significant.
Table 3 Summary of evening (evening reflective) total symptoms score (5TSS) assessments and nasal total symptoms score (4NTSS) 
(iTT population)
  Placebo Rupatadine 
10 mg
Rupatadine 
20 mg
Cetirizine 
10 mg
ANOVA
Mean SEM Mean SEM Mean SEM Mean SEM P value
Baseline 5 Tss 6.96 0.36 6.62 0.36 6.28 0.37 6.23 0.36 ns
4 Tnss 6.15 0.30 5.65 0.32 5.50 0.33 5.45 0.31 ns
2 weeks 5Tss 5.47 0.34 3.92** 0.24 3.52** 0.26 3.69** 0.29 ,0.001
4nTss 4.89 0.30 3.44** 0.21 3.17** 0.23 3.16** 0.23 ,0.001
4 weeks 5Tss 5.35 0.37 3.58** 0.24 3.20** 0.25 3.48** 0.31 ,0.001
4nTss 4.81 0.33 3.11** 0.20 2.86** 0.23 3.00** 0.25 ,0.001
change from baseline  
(4 weeks)
5Tss
4nTss
−1.62
−1.37
0.33
0.28
−3.10**
−2.55**
0.37
0.32
−3.06**
−2.62**
0.36
0.31
−2.75*
−2.44*
0.37
0.32
0.011
0.012
% change from baseline 5Tss −25.7 4.3 −40.7* 4.9 −49.9** 3.9 −40.1* 4.7 0.003
4nTss −25.4 4.0 −40.7* 4.2 −44.9** 5.5 −39.9* 4.8 0.018
Notes: *P , 0.05 vs placebo; **P , 0.01 vs placebo.
Abbreviation: NS, not significant.Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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that the worse symptoms were most severe in the morning 
significantly more often than those with seasonal AR.11 
Therefore, to maximize the benefits for patients and to 
maintain a good overall efficacy and safety profile, any 
pharmacologic agent used in the management of AR should 
be effective in controlling these peak morning symptoms. 
In general, antihistamines would be expected to exert their 
maximum effect near or shortly after peak serum levels are 
reached. Previous studies with rupatadine showed a fast 
onset of action,6 due to the fact that peak serum levels were 
reached around 0.5 to 1 hour after dosing.7 This was the 
principal reason that morning dosing was scheduled in our 
0.00
Rhinorrhea Nasal itching Nasal obstruction
Evening symptoms
Sneezing
Placebo
Rupatadine 10 mg
Rupatadine 20 mg
Cetirizine 10 mg
Conjunctival itching
0.25
0.50
0.75
1.00
1.25
1.50
B
0.00
Rhinorrhea Nasal itching Nasal obstruction
Morning symptoms
Sneezing
Placebo
Rupatadine 10 mg
Rupatadine 20 mg
Cetirizine 10 mg
Conjunctival itching
0.25
0.50
0.75
1.00
**
**
**
**
**
** ** **
**
**
** **
**
**
**
**
*
**
**
1.25
1.50
A
Figure 2 symptom scores: A) Morning evaluation for each individual symptom at 4 weeks; B) evening evaluation for each individual symptom at 4 weeks. 
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Figure 3 evolution of total symptoms score (5Tss): A) morning evaluation for the 5Tss scores during study period; B) evening evaluation for the 5Tss scores during the 
study period.
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patients. In spite of this fact, we expected to observe the most 
relief in morning symptoms in comparison with evening 
symptoms. But overall relief of symptoms was equivalent 
for morning or evening with rupatadine 10 or 20 mg once 
daily, indicating that the sustained 24-hour effects of 
rupatadine are independent of time of dosing. A similar 
morning/evening profile was observed for cetirizine 10 mg 
treatment compared with rupatadine 10 mg. Nevertheless, 
the percentage reduction for both total symptoms and nasal 
symptoms score was not significant with cetirizine compared 
with placebo at morning evaluations, whereas the reduction 
was statistically significant with both rupatadine doses.
When individual symptoms were evaluated at morning 
or evening, as secondary endpoints, nasal obstruction and 
conjunctival itching did not show a significant reduction 
with rupatadine 10 mg and cetirizine 10 mg compared with 
  placebo. Only rupatadine 20 mg provided a   significant 
capacity for alleviating nasal congestion at morning 
evaluation. Nasal congestion is a particularly troublesome 
symptom of AR and often is cited by patients as the most 
bothersome symptom. However, newer antihistamines have 
demonstrated anti-inflammatory properties, and the results of 
clinical trials of their effects on nasal congestion are mixed.12 
Rupatadine has been shown to reduce effectively nasal Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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congestion in patients with seasonal AR, whether measured 
objectively as nasal airflow or subjectively as symptoms in 
allergen exposure study.13,14
The specific mechanisms underlying the chronobiology 
of AR are speculative; however several factors might 
  contribute to the occurrence of maximum nasal congestion: 
sneezing rhinorrhea in the morning; secretions increase and 
accumulate overnight; there is continuous allergen exposure 
to mold, mites, or house dander; cortisol levels are lowest 
at night, and hence inflammatory mediators might be at 
high levels; and autonomic nervous system activity at night 
promotes vagal tone, favoring vasodilation.15
Differences in daytime and night-time administration 
of first-generation antihistamines have been reported long 
time ago and may represent a class effect.16 First-generation 
H1 antihistamines effectively reduce AR symptoms but 
worsen daytime somnolence, decrease reaction time, 
and impair performance.17 Older antihistamines also 
worsen sleep architecture and disrupt the normal sleep 
process, and therefore the patients wake up feeling 
unrested.18,19 Administration time-dependent differences 
in the pharmacokinetics, especially duration and time to 
pick effect, between the first-generation antihistamines 
and the second-generation antihistamines have also been 
demonstrated.9 The second-generation antihistamines have 
a rapid onset of action and are not known to interfere with 
sleep. A study with desloratadine in seasonal AR showed 
no statistically significant difference in efficacy when the 
compound was given in the morning or in the evening.2 
Rupatadine administered in the morning improves daytime 
and night-time symptoms, despite rupatadine not being 
administered at bedtime in this study, and therefore it is 
impossible to determine chronotherapeutic benefit to evening 
versus morning dosing of rupatadine.
It is well recognized that second-generation antihistamines 
are generally nonsedating therapies; however this does not 
mean that somnolence never occurs with these therapies. 
Indeed, nonsedating second-generation antihistamines 
with zero somnolence do not exist. Rather, somnolence is 
reported in a small minority of patients, which means second-
generation antihistamines are nonsedating compared with 
first-generation ones.
It should be noted that in our trial, at the end of each 
weekly treatment period, patients were actively asked to 
report any adverse symptom or event that they may have 
experienced. This can lead to an ‘over-reporting’ of adverse 
event frequency in comparison with those studies in which 
patients have reported adverse events spontaneously. The 
increase in the incidence of sleepiness, as a treatment-related 
adverse event, could be associated with the administration 
of the drug in the morning. The time of drug administration 
in our study differs from that of other similar trials carried 
out with other recent second-generation antihistamines, in 
which the drug in usually taken at bedtime.20
In conclusion, the sustained 24-hour action of rupatadine 
10 mg provides an effective control of morning and evening 
symptoms in patients with PAR treated for up to 4 weeks.
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Table 4 incidence of adverse events reported by 1% during the study by treatment group
Placebo 
(n = 70)
Rupatadine 10 mg  
(n = 65)
Rupatadine 20 mg  
(n = 68)
Cetirizine 10 mg 
(n = 66)
headache 15 (21%) 13 (20%) 8 (12%) 15 (23%)
somnolence 0  7 (11%)* 14 (20%)** 4 (6%)
Fatigue/asthenia 4 (6%) 10 (15.5%) 6 (9%) 5 (7.5%)
Abdominal pain 3 (4%) 3 (4.5%) 6 (9%) 3 (4.5%)
Back pain 5 (7%) 3 (4.5%) 1 (1.5%) 3 (4.5%)
Notes: Data shown are number and percentage of patients affected in each treatment group. *P , 0.01 vs placebo; **P , 0.001 vs placebo.Journal of Asthma and Allergy
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